Literature DB >> 32245040

The Multifactorial Role of PARP-1 in Tumor Microenvironment.

Juan Manuel Martí1, Mónica Fernández-Cortés1, Santiago Serrano-Sáenz1, Esteban Zamudio-Martinez1, Daniel Delgado-Bellido1, Angel Garcia-Diaz1, Francisco Javier Oliver1.   

Abstract

Poly(ADP-ribose) polymerases (PARPs), represent a family of 17 proteins implicated in a variety of cell functions; some of them possess the enzymatic ability to synthesize and attach poly (ADP-ribose) (also known as PAR) to different protein substrates by a post-translational modification; PARPs are key components in the cellular response to stress with consequences for different physiological and pathological events, especially during neoplasia. In recent years, using PARP inhibitors as antitumor agents has raised new challenges in understanding their role in tumor biology. Notably, the function of PARPs and PAR in the dynamic of tumor microenvironment is only starting to be understood. In this review, we summarized the conclusions arising from recent studies on the interaction between PARPs, PAR and key features of tumor microenvironment such as hypoxia, autophagy, tumor initiating cells, angiogenesis and cancer-associated immune response.

Entities:  

Keywords:  PARP inhibitors; PARPs; PARylation; Tumor microenvironment; autophagy; hypoxia

Year:  2020        PMID: 32245040     DOI: 10.3390/cancers12030739

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  9 in total

Review 1.  PARkinson's: From cellular mechanisms to potential therapeutics.

Authors:  Zsofia Lengyel-Zhand; Laura N Puentes; Robert H Mach
Journal:  Pharmacol Ther       Date:  2021-08-12       Impact factor: 12.310

2.  PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality-An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness.

Authors:  Patrycja Gralewska; Arkadiusz Gajek; Agnieszka Marczak; Michał Mikuła; Jerzy Ostrowski; Agnieszka Śliwińska; Aneta Rogalska
Journal:  Int J Mol Sci       Date:  2020-12-19       Impact factor: 5.923

3.  PARPs, PAR and NAD Metabolism and Their Inhibitors in Cancer.

Authors:  Nicola Curtin; Péter Bai
Journal:  Cancers (Basel)       Date:  2020-11-24       Impact factor: 6.639

4.  Short-term starvation synergistically enhances cytotoxicity of Niraparib via Akt/mTOR signaling pathway in ovarian cancer therapy.

Authors:  Wang Zhi; Suting Li; Yuting Wan; Fuwen Wu; Li Hong
Journal:  Cancer Cell Int       Date:  2022-01-11       Impact factor: 6.429

Review 5.  PARP-1-Associated Pathological Processes: Inhibition by Natural Polyphenols.

Authors:  Natalya V Maluchenko; Alexey V Feofanov; Vasily M Studitsky
Journal:  Int J Mol Sci       Date:  2021-10-23       Impact factor: 5.923

6.  Accumulation of poly (adenosine diphosphate-ribose) by sustained supply of calcium inducing mitochondrial stress in pancreatic cancer cells.

Authors:  Keun-Yeong Jeong; Jae Jun Sim; Minhee Park; Hwan Mook Kim
Journal:  World J Gastroenterol       Date:  2022-07-21       Impact factor: 5.374

Review 7.  Improving PARP inhibitor efficacy in high-grade serous ovarian carcinoma: A focus on the immune system.

Authors:  Nirashaa T Bound; Cassandra J Vandenberg; Apriliana E R Kartikasari; Magdalena Plebanski; Clare L Scott
Journal:  Front Genet       Date:  2022-09-09       Impact factor: 4.772

Review 8.  The Significance of Targeting Poly (ADP-Ribose) Polymerase-1 in Pancreatic Cancer for Providing a New Therapeutic Paradigm.

Authors:  Keun-Yeong Jeong; Min Hee Park
Journal:  Int J Mol Sci       Date:  2021-03-29       Impact factor: 5.923

9.  PARP1 Inhibitor and Trabectedin Combination Does Not Increase Tumor Mutational Burden in Advanced Sarcomas-A Preclinical and Translational Study.

Authors:  Ymera Pignochino; Giovanni Crisafulli; Giorgia Giordano; Alessandra Merlini; Enrico Berrino; Maria Laura Centomo; Giulia Chiabotto; Silvia Brusco; Marco Basiricò; Elena Maldi; Alberto Pisacane; Valeria Leuci; Dario Sangiolo; Lorenzo D'Ambrosio; Massimo Aglietta; Bernd Kasper; Alberto Bardelli; Giovanni Grignani
Journal:  Cancers (Basel)       Date:  2021-12-15       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.